New vaccine combo shows promise for Hard-to-Treat cancers
NCT ID NCT05631899
First seen Jan 10, 2026 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This early-stage trial tests a custom-made vaccine using a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given together with two immunotherapy drugs to boost the immune system's attack on tumors. The study includes about 9 adults with advanced solid tumors that have not responded to standard treatments, and aims to check safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Biotherapeutic Department of Chinsese PLA Gereral Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.